Selexis and Inotrem Enter Service Agreement to Advance Inotrem’s Chronic Inflammatory Disease Program

Geneva, Switzerland, and Paris, France, January 19, 2022Selexis SA, a JSR Life Sciences company, and Inotrem SA, an advanced clinical-stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, have signed a service agreement to develop the cell line for Inotrem’s antibody-based candidate to address chronic inflammations. Under the agreement terms, Inotrem will leverage Selexis’ proprietary SUREtechnology PlatformTM, a suite of cell line development technologies that significantly reduces the time, effort, and costs associated with developing high-performance mammalian cell lines.

Read full article (PDF)